Directorate Change

RNS Number : 2986C

Shield Therapeutics PLC

18 June 2021

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

Directorate Change

London, UK, 18 June 2021:  Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that further to the announcement issued on 28 May 2021, Greg Madison will join the Board with immediate effect and is fulfilling the role of the Group's Chief Executive Officer.

Shield also discloses the following information in accordance with Schedule 2(g) of the AIM Rules for Companies.

Full name: Gregory Paul Madison

Age: 53 years

Current directorships/partnerships:

· American Kidney Fund, Board of Trustees 

Previous directorships/partnerships held in the past 5 years:

· Melt Pharmaceuticals, Inc.

· Keryx Biopharmaceuticals, Inc.

· Keryx Biopharma UK Ltd.

Mr Madison currently does not hold any ordinary shares in Shield.

There are no other disclosures required in connection with the appointment of Mr Madison under Schedule Two(g) of the Aim Rules for Companies.

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Greg Madison, CEO	[phone]
Lucy Huntington-Bailey
Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Christopher Golden	[phone]
Joint Broker finnCap Ltd  Geoff Nash/Alice Lane/George Dollemore	[phone]
Financial PR & IR Advisor
Walbrook PR	[phone] or  [e-mail]
Paul McManus/Lianne Cawthorne

About Shield Therapeutics plc

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx

 

END

 

 

BOAMZGMVKNLGMZM